The impact of body composition on treatment in ovarian cancer: a current insight

References

• Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134–140.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38(32):3753–3762.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch. 2000 Feb;67(1):5–8.
   PubMedGoogle Scholar
• Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–1505.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–1259.
   PubMed Web of Science ®Google Scholar
• Bartels HC, Rogers AC, McSharry V, et al. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019;154(3):622–630.
   PubMed Web of Science ®Google Scholar
• Bacalbasa N, Balescu I, Dimitriu M, et al. The influence of the preoperative status on the risk of postoperative complications after cytoreductive surgery for advanced-stage ovarian cancer. Vivo. 2020;34(2):839–844.
   PubMed Web of Science ®Google Scholar
• Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134(1):36–42.
   PubMedGoogle Scholar
• Hu WH, Cajas-Monson LC, Eisenstein S, et al. Preoperative malnutrition assessments as predictors of postoperative mortality and morbidity in colorectal cancer: an analysis of ACS-NSQIP. Nutr J. 2015;14:91.
   PubMed Web of Science ®Google Scholar
• Kumar A, Janco JM, Mariani A, et al. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2016 Jan;140(1):15–21. .
   PubMed Web of Science ®Google Scholar
• Pache B, Grass F, Hubner M, et al. Prevalence and consequences of preoperative weight loss in gynecologic surgery. Nutrients. 2019;11:5.
   Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.
   PubMed Web of Science ®Google Scholar
• Thompson KL, Elliott L, Fuchs-Tarlovsky V, et al. Oncology evidence-based nutrition practice guideline for adults. J Acad Nutr Diet. 2017;117(2):297–310.e47.
   PubMed Web of Science ®Google Scholar
• Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;1:CD005340.
   Google Scholar
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–1466.
   PubMed Web of Science ®Google Scholar
• Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27–32.
   PubMed Web of Science ®Google Scholar
• Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12(1):98.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–2415.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317–2328.
   PubMed Web of Science ®Google Scholar
• Gonzalez Martin A, Oza AM, Embleton AC, et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol. 2019;152(1):53–60.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Colombo N, Oza AM, et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial [Scientific Plenary]. Gynecol Oncol. 2020;159.
   Web of Science ®Google Scholar
• Moore K, Bookman M, Sehouli J, et al. Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy ± atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) [Abstract]. Ann Oncol. 2020;31:S1161–S1162.
   Web of Science ®Google Scholar
• Mourtzakis M, Prado CMM, Lieffers JR. et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. App Physiol Nutr Metab. 2008;33(5):997–1006.
   PubMed Web of Science ®Google Scholar
• Ryan AM, Power DG, Daly L, et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75(2):199–211.
   PubMed Web of Science ®Google Scholar
• Matsubara Y, Nakamura K, Matsuoka H, et al. Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer. Mol Clin Oncol. 2019;11(4):376–382.
   PubMed Web of Science ®Google Scholar
• Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):630–638.
   PubMed Web of Science ®Google Scholar
• Sebro R, O’Brien L, Torriani M, et al. Assessment of trunk muscle density using CT and its association with degenerative disc and facet joint disease of the lumbar spine. Skeletal Radiol. 2016;45(9):1221–1226.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
   PubMed Web of Science ®Google Scholar
• Rong S, Wang L, Peng Z, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? J Cachexia Sarcopenia Muscle. 2020;11(2):348–365.
   PubMed Web of Science ®Google Scholar
• Rutten IJG, Dpj VD, Kruitwagen RFPM, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016;7(4):458–466.
   PubMed Web of Science ®Google Scholar
• McSharry V, Mullee A, McCann L, et al. The impact of sarcopenia and low muscle attenuation on overall survival in epithelial ovarian cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2020;27(9):3553–3564.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–106.
   PubMed Web of Science ®Google Scholar
• Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016;142(2):311–316.
   PubMed Web of Science ®Google Scholar
• ECR DMV, Oliveira IDS, Rechinelli AB, et al. Malnutrition and nutrition impact symptoms (NIS) in surgical patients with cancer. PLoS ONE. 2020;15(12):e0241305.
   PubMed Web of Science ®Google Scholar
• Laky B, Janda M, Bauer J, et al. Malnutrition among gynaecological cancer patients. Eur J Clin Nutr. 2007 May;61(5):642–646.
   PubMed Web of Science ®Google Scholar
• Balogun N, Forbes A, Widschwendter M, et al. Noninvasive nutritional management of ovarian cancer patients beyond intestinal obstruction. Int J Gynecol Cancer. 2012 Jul;22(6):1089–1095.
   PubMed Web of Science ®Google Scholar
• Yim GW, Eoh KJ, Kim SW, et al. Malnutrition identified by the nutritional risk index and poor prognosis in advanced epithelial ovarian carcinoma. Nutr Cancer. 2016;68(5):772–779.
   PubMed Web of Science ®Google Scholar
• Mizrahi D, Naumann F, Broderick C, et al. Quantifying physical activity and the associated barriers for women with ovarian cancer. Int J Gynecol Cancer. 2015;25(4):577.
   PubMed Web of Science ®Google Scholar
• Lin K-Y, Edbrooke L, Granger CL. et al. The impact of gynaecological cancer treatment on physical activity levels: a systematic review of observational studies. Baz J Phys Ther. 2019;23(2):79–92.
   PubMed Web of Science ®Google Scholar
• Mijnarends DM, Koster A, Schols JM, et al. Physical activity and incidence of sarcopenia: the population-based AGES-Reykjavik Study. Age Ageing. 2016;45(5):614–620.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Stuart CA, Brunder DG, et al. Magnetic resonance imaging quantitation of changes in muscle volume during 7 days of strict bed rest. Aviat Space Environ Med. 1995;66(10):976–981.
   PubMedGoogle Scholar
• Tanner RE, Brunker LB, Agergaard J, et al. Age-related differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise rehabilitation. J Physiol. 2015;593(18):4259–4273.
   PubMed Web of Science ®Google Scholar
• Caan BJ, Meyerhardt JA, Kroenke CH. et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS Study). Cancer Epidem Biomar. 2017;26(7):1008–1015.
   PubMed Web of Science ®Google Scholar
• Daly LE, Power DG, O’Reilly A, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116(3):310–317.
   PubMed Web of Science ®Google Scholar
• Prado CM, Cushen SJ, Orsso CE, et al. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188–198.
   PubMed Web of Science ®Google Scholar
• Daly LE, Ni Bhuachalla EB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):315–325.
   PubMed Web of Science ®Google Scholar
• Allanson ER, Peng Y, Choi A, et al. A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy. Int J Gynecol Cancer. 2020;30(11):1791–1797.
   PubMed Web of Science ®Google Scholar
• Ubachs J, Ziemons J, IJG M-R, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Fagotti A, Cintoni M, et al. Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2020;30(5):654–663.
   PubMed Web of Science ®Google Scholar
• Ataseven B, Luengo TG, du Bois A, et al. Skeletal muscle attenuation (sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary debulking surgery. Ann Surg Oncol. 2018;25(11):3372–3379.
   PubMed Web of Science ®Google Scholar
• Aust S, Knogler T, Pils D, et al. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS ONE. 2015;10(10):e0140403.
   PubMed Web of Science ®Google Scholar
• Bronger H, Hederich P, Hapfelmeier A, et al. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer. 2017;27(2):223–232.
   PubMed Web of Science ®Google Scholar
• Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol. 2017;43(4):717–724.
   PubMed Web of Science ®Google Scholar
• Staley SA, Tucker K, Newton M, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020;156(3):695–700.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, Xiao J. et al. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39(6):693–698.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Takano M, Miyamoto M, et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol. 2017;80(3):555–561.
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Sun F-J LJ. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer. Nutr. 2020;72:110642.
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Yang Y-C, Chen T-C, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):534–546.
   PubMed Web of Science ®Google Scholar
• Zamboni M, Gattazzo S, Rossi AP. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur Geriatr Med. 2019;10(1):5–6.
   PubMed Web of Science ®Google Scholar
• Stephens NA, Skipworth RJE, Macdonald AJ, et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(2):111–117.
   PubMed Web of Science ®Google Scholar
• Malietzis G, Johns N, Al-Hassi HO, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg. 2016;263(2):320–325.
   PubMed Web of Science ®Google Scholar
• Miljkovic I, Cauley JA, Wang PY, et al. Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obesity. 2013;21(10):2118–2125.
   PubMed Web of Science ®Google Scholar
• Beaudart C, McCloskey E, Bruyère O, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):170.
   PubMed Web of Science ®Google Scholar
• Santa Mina D, van Rooijen SJ, Minnella EM, et al. Multiphasic prehabilitation across the cancer continuum: a narrative review and conceptual framework. Front Oncol. 2021;10:2978.
   Web of Science ®Google Scholar
• Gillis C, Fenton TR, Sajobi TT, et al. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: a pooled analysis of randomized controlled trials. Clin Nutr. 2019;38(3):1053–1060.
   PubMed Web of Science ®Google Scholar
• Moug SJ, Barry SJE, Maguire S, et al. Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A subanalysis from the REx randomised controlled trial. Tech Coloproctol. 2020;24(9):959–964.
   PubMed Web of Science ®Google Scholar
• Frontera WR, Zayas AR, Rodriguez N. Aging of human muscle: understanding sarcopenia at the single muscle cell level. Phys Med Rehabil Clin N Am. 2012;23(1):201–xiii.
   PubMed Web of Science ®Google Scholar
• Fadadu PP, Polen-De CL, McGree ME, et al. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: an opportunity for prehabilitation. Gynecol Oncol. 2021 Jan;160(1):40–44.
   PubMed Web of Science ®Google Scholar
• Pamoukdjian F, Bouillet T, Lévy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37(4):1101–1113.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
   PubMed Web of Science ®Google Scholar
• Martin L, Gioulbasanis I, Senesse P. et al. Cancer-associated malnutrition and CT-defined sarcopenia and myosteatosis are endemic in overweight and obese patients. J Parenter Enteral Nutr. 2020;44(2):227–238.
   PubMed Web of Science ®Google Scholar
• Ubachs J, Koole SN, Lahaye M, et al. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. Gynecol Oncol. 2020;159(3):706–711.
   PubMed Web of Science ®Google Scholar
• Zhuang C-L, Shen X, Huang -Y-Y, et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score–matched analysis from a large-scale cohort. Surgery. 2019;166(3):297–304.
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–465.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Iwahashi Y, Miyai H, et al. Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer. Sci Rep. 2020;10(1):22146.
   PubMed Web of Science ®Google Scholar
• McSorley ST, Black DH, Horgan PG, et al. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin Nutr. 2018;37(4):1279–1285.
   PubMed Web of Science ®Google Scholar
• Silva De Paula N, de Aguiar Bruno K, Azevedo AM, et al. Sarcopenia and skeletal muscle quality as predictors of postoperative complication and early mortality in gynecologic cancer. Int J Gynecol Cancer. 2018;28(2):412–420.
   PubMed Web of Science ®Google Scholar
• Nakayama N, Nakayama K, Nakamura K, et al. Sarcopenic factors may have no impact on outcomes in ovarian cancer patients. Diagnostics. 2019;9:4.
   Web of Science ®Google Scholar
• Conrad LB, Awdeh H, Acosta-Torres S, et al. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J Surg Oncol. 2018;117(5):1020–1028.
   PubMed Web of Science ®Google Scholar
• Torres ML, Hartmann LC, Cliby WA, et al. Nutritional status, CT body composition measures and survival in ovarian cancer. Gynecol Oncol. 2013;129(3):548–553.
   PubMed Web of Science ®Google Scholar
• Ryan AM, Prado CM, Sullivan ES, et al. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutr. 2019;67–68:110539.
   PubMed Web of Science ®Google Scholar
• Daly LE, Prado CM, Ryan AM. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018;77(2):135–151.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Taguchi A, Nakajima Y, et al. Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients. J Obstet Gynaecol Res. 2020;46(12):2662–2671.
   Web of Science ®Google Scholar
• Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. Expert Rev Clin Pharmacol. 2017;10(9):947–956.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Fanucchi A, et al. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res. 2001;21:2941–2947.
   PubMed Web of Science ®Google Scholar
• Dickerson RN, White KG, Curcillo PG 2nd, et al. Resting energy expenditure of patients with gynecologic malignancies. J Am Coll Nutr. 1995;14(5):448–454.
   PubMed Web of Science ®Google Scholar
• Kortebein P, Symons TB, Ferrando A, et al. Functional impact of 10 days of bed rest in healthy older adults. J Gerontol A Biol Sci Med Sci. 2008;63(10):1076–1081.
   PubMed Web of Science ®Google Scholar
• Silver JK, Cancer Prehabilitation: BJ. An opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013;92(8):715–727.
   PubMed Web of Science ®Google Scholar
• Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: enhanced recovery after surgery (ERAS) society recommendations—2019 update. Int J Gynecol Cancer. 2019. DOI:https://doi.org/10.1136/ijgc-2019-000356.
   Google Scholar
• Treanor C, Kyaw T, Donnelly M. An international review and meta-analysis of prehabilitation compared to usual care for cancer patients. J Cancer Surviv. 2018;12(1):64–73.
   PubMed Web of Science ®Google Scholar
• Gillis C, Buhler K, Bresee L, et al. Effects of nutritional prehabilitation, with and without exercise, on outcomes of patients who undergo colorectal surgery: a systematic review and meta-analysis. Gastroenterology. 2018;155(2):391–410.e4.
   PubMed Web of Science ®Google Scholar
• Lambaudie E, Bannier Braticevic C, Villaron Goetgheluck C, et al. TRAINING-ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program. Int J Gynecol Cancer. 2020. DOI:https://doi.org/10.1136/ijgc-2020-002128.
   Google Scholar
• Stelten S, Hoedjes M, Kenter GG, et al. Rationale and study protocol of the Physical Activity and Dietary intervention in women with OVArian cancer (PADOVA) study: a randomised controlled trial to evaluate effectiveness of a tailored exercise and dietary intervention on body composition, physical function and fatigue in women with ovarian cancer undergoing chemotherapy. BMJ Open. 2020;10(11):e036854.
   PubMed Web of Science ®Google Scholar
• Dreyer HC, Drummond MJ, Pennings B, et al. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab. 2008;294(2):E392–E400.
   PubMed Web of Science ®Google Scholar
• Campbell K, Winters-Stone K, Patel A, et al. An Executive Summary of Reports From an International Multidisciplinary Roundtable on Exercise and Cancer: evidence, Guidelines, and Implementation. Rehabil Oncol. 2019;37:144–152.
   Web of Science ®Google Scholar
• Bruno E, Roveda E, Vitale J, et al. Effect of aerobic exercise intervention on markers of insulin resistance in breast cancer women. Eur J Cancer Care. 2018;27(2):e12617.
   PubMed Web of Science ®Google Scholar
• Meneses-Echávez JF, Correa-Bautista JE, González-Jiménez E. et al. The effect of exercise training on mediators of inflammation in breast cancer survivors: a systematic review with meta-analysis. Cancer Epidemol Biomarkers Prev. 2016;25(7):1009.
   PubMed Web of Science ®Google Scholar
• Prado CM, Anker SD, Coats AJS, et al. Nutrition in the spotlight in cachexia, sarcopenia and muscle: avoiding the wildfire. J Cachexia Sarcopenia Muscle. 2021;12(1):3–8.
   PubMed Web of Science ®Google Scholar
• Guadagni M, Biolo G. Effects of inflammation and/or inactivity on the need for dietary protein. Curr Opin Clin Nutr Metab Care. 2009;12(6):617–622.
   PubMed Web of Science ®Google Scholar
• Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):366–380.
   PubMed Web of Science ®Google Scholar
• Ewaschuk JB, Almasud A, Mazurak VC. Role of n-3 fatty acids in muscle loss and myosteatosis. Appl Physiol Nutrit Metab. 2014;39(6):654–662.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264–3268.
   PubMed Web of Science ®Google Scholar